INSTACLOP 75

Indications

• Cerebral edema
• Elevated intracranial pressure
• Acute kidney injury
• Oliguria
• Glaucoma
• Renal function diagnostic aid

Dosage

Adults: For cerebral edema, administer 0

Mechanism of action

Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. This action reduces cerebral edema and intracranial pressure. As a diuretic, it increases the osmolality of glomerular filtrate, leading to increased urinary excretion of water and preventing sodium and chloride reabsorption in the renal tubules. Mannitol also facilitates the urinary excretion of toxic substances and can help in assessing renal function by measuring glomerular filtration rate (GFR).

Pharmacodynamics

Mannitol is classified as an osmotic diuretic. It is chemically similar to other sugar alcohols but has a unique ability to promote diuresis by remaining unabsorbed in the renal tubules. Its use is indicated for conditions associated with increased body fluids, such as cerebral edema and glaucoma. Mannitol may be combined with other diuretics to enhance diuretic efficacy. Inhaled formulations are used in cystic fibrosis, though they may cause bronchospasm and hemoptysis.

Pharmacokinetics

Mannitol is freely filtered by the glomeruli with less than 10% tubular reabsorption, which allows for its urinary excretion rate to serve as a measurement of GFR. It does not undergo significant metabolism and is eliminated primarily through the kidneys. The onset of action occurs within 30 to 60 minutes after intravenous administration, with effects lasting for several hours. Administration may require monitoring of renal function and fluid balance.

Contra-indications

• Anuria
• Severe dehydration
• Severe renal impairment
• Intracranial bleeding

Adverse effects

• Asthenia
• Gastrointestinal disturbances
• Dry mouth
• Confusion
• Visual impairment
• Hypotension
• Electrolyte imbalances
• Pulmonary edema
• Hemoptysis (with inhalation use)
• Bronchospasm (with inhalation use)

Interactions

• Potassium-sparing diuretics may increase the risk of hyperkalemia
• Other diuretics may have additive effects
• Caution with nephrotoxic agents

Precautions

• Caution in patients with diabetes mellitus
• Caution in the elderly
• Caution in patients with gout
• Caution in patients with hepatic impairment
• Monitor renal function and electrolytes regularly
• May cause blue fluorescence of urine

Pregnancy

Manufacturer advises avoid due to potential toxicity in animal studies.

Breast-feeding

Manufacturer advises avoid due to lack of information available.

Storage

Store in a cool, dry place, away from light. Do not freeze.

Formulations

• Solution for injection
• Inhalation powder
• Oral solution

Indications

• Prevention of atherothrombotic events in patients with acute coronary syndrome
• Secondary prevention of ischaemic stroke
• Prevention of atherothrombotic events in peripheral arterial disease

Mechanism of action

Clopidogrel is activated through a two-step metabolic process to form an active thiol-containing metabolite. This metabolite irreversibly binds to the P2Y12 ADP receptors on platelets, preventing ADP from activating the GPIIb/IIIa complex, which is crucial for platelet aggregation. As a result, clopidogrel inhibits platelet aggregation for the lifespan of the platelets (approximately 7 to 10 days). The inhibition of the P2Y12 receptor reduces platelet activation and aggregation not just from ADP, but also from other agonists.

Pharmacodynamics

Clopidogrel is a prodrug that serves as a potent antiplatelet agent, effectively reducing the risk of myocardial infarction and stroke. Its pharmacological effects are long-lasting, allowing for once-daily dosing. Clopidogrel exhibits a broad therapeutic window, and its dosage ranges from 75 mg to 300 mg per day, depending on the clinical scenario. Its action helps maintain blood flow and prevent occlusive vascular events.

Pharmacokinetics

Clopidogrel is well absorbed in the gastrointestinal tract, with peak plasma concentrations occurring within 1 to 2 hours after oral administration. It undergoes extensive hepatic metabolism, primarily through CYP450 enzymes, which convert it into its active form. The elimination half-life of clopidogrel is approximately 6 hours, but the antiplatelet effect lasts much longer due to the irreversible nature of its action on platelets. It is primarily excreted through urine, with a majority of the dose eliminated as inactive metabolites.

Contra-indications

• Active bleeding

Adverse effects

• Confusion
• Fever
• Gynaecomastia
• Hallucination
• Hepatic disorders
• Hypotension
• Myalgia
• Neutropenia
• Severe cutaneous adverse reactions (SCARs)
• Stomatitis
• Taste altered
• Ulcerative colitis
• Vasculitis
• Vertigo
• Wound haemorrhage

Interactions

• Voriconazole + clopidogrel: Severe (decreases efficacy)
• HIV protease inhibitors + clopidogrel: Severe (decreases efficacy)
• Moclobemide + clopidogrel: Severe (decreases efficacy)
• Ritonavir + clopidogrel: Severe (decreases efficacy)
• Clopidogrel + pioglitazone: Moderate (increases exposure)
• Clopidogrel + treprostinil: Moderate (increases exposure)
• Clopidogrel + apalutamide: Unknown (increases exposure)
• Clopidogrel + enzalutamide: Unknown (increases exposure)
• Fluconazole + clopidogrel: Unknown (decreases efficacy)
• Clopidogrel + anti-androgens: Unknown (increases exposure)

Precautions

• Caution with history of hypersensitivity reactions to thienopyridines
• Caution in moderate hepatic impairment
• Caution in renal impairment
• Discontinue 7 days before elective surgery if antiplatelet effect not desirable
• Patients at risk of increased bleeding from trauma, surgery, or other pathological conditions

Pregnancy

Manufacturer advises avoid-no information available.

Breast-feeding

Manufacturer advises avoid.

Storage

Store in a cool, dry place, away from direct sunlight.

Formulations

• Clopidogrel 75 mg tablet
• Clopidogrel 300 mg tablet
• Clopidogrel oral suspension

Indications

• Food preservation
• Antioxidant applications
• Reduction of oxidative stress

Dosage

Children: Refer to specific guidelines or consult a healthcare professional for dosing recommendations, as doses can vary based on the indication.

Adults: Refer to specific guidelines or consult a healthcare professional for dosing recommendations, as doses can vary based on the indication.

Mechanism of action

Bisulphate acts as a reducing agent, donating electrons to other molecules, which can help in neutralizing free radicals and preventing oxidative stress. It interacts with sulfite oxidase in the body, facilitating the conversion of sulfite to sulfate, a less toxic form. This mechanism is particularly relevant in the context of sulfite metabolism and detoxification.

Pharmacodynamics

Bisulphate's pharmacodynamics are primarily related to its antioxidant properties. It helps to protect cells from oxidative damage by scavenging free radicals. The compound also plays a role in maintaining the acid-base balance in the body, as it can act as a buffer in certain physiological conditions.

Pharmacokinetics

Bisulphate is rapidly absorbed and metabolized in the body. It is primarily metabolized in the liver, where it is converted to sulfate. The elimination route is mainly through urine, where it is excreted as sulfate. The half-life of bisulphate is short, necessitating frequent dosing in certain applications.

Adverse effects

• Headache
• Nausea
• Diarrhea
• Skin rash
• Hypersensitivity reactions

Precautions

• Use with caution in patients with asthma or respiratory issues
• Monitor for allergic reactions in sensitive individuals

Pregnancy

The safety of bisulphate during pregnancy has not been established. Use only if clearly needed and after assessing risks versus benefits.

Breast-feeding

It is not known whether bisulphate is excreted in human milk. Caution is advised when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Dosage

Children: Refer to specific product information for dosing guidelines.

Adults: Refer to specific product information for dosing guidelines.

Pregnancy

Consult healthcare provider for specific information regarding use during pregnancy.

Breast-feeding

Consult healthcare provider for specific information regarding use during breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Constipation
• Labor induction
• Topical treatment for skin conditions

Dosage

Children: Refer to the BNF for Children for appropriate pediatric dosing guidelines, as no specific doses are provided.

Adults: Refer to specific guidelines for adult dosing based on the formulation used and the condition being treated, as no standardized dose is provided.

Mechanism of action

Ricinoleic acid, the main active component of castor oil, acts as a stimulant laxative. It works by increasing the peristaltic movement of the intestines, which aids in the evacuation of stool. Additionally, it may inhibit the absorption of water in the intestines, resulting in softer stools. The oil is also believed to have anti-inflammatory properties, which can be beneficial in treating certain skin conditions.

Pharmacodynamics

The pharmacodynamic properties of castor oil include its ability to stimulate intestinal motility and increase the secretion of intestinal fluids. This leads to a faster transit time for stool through the bowel. In topical applications, castor oil exhibits emollient and moisturizing effects, promoting healing and soothing irritated skin. Its anti-inflammatory effects may also contribute to the reduction of swelling and pain in inflamed tissues.

Pharmacokinetics

Castor oil is absorbed in the gastrointestinal tract, where it is metabolized to ricinoleic acid. The onset of action for its laxative effect typically occurs within 2 to 6 hours after oral administration. The duration of action varies, but effects usually last for several hours. When applied topically, castor oil penetrates the skin and may provide localized effects without significant systemic absorption.

Adverse effects

• Abdominal cramps
• Diarrhea
• Nausea
• Vomiting
• Dehydration

Precautions

• Use with caution in patients with gastrointestinal disorders
• Not recommended for prolonged use
• Monitor for signs of dehydration

Pregnancy

Castor oil is generally not recommended during pregnancy due to potential uterine contractions and risk of premature labor.

Breast-feeding

Castor oil should be used with caution during breastfeeding as it may cause gastrointestinal discomfort in nursing infants.

Storage

Store in a cool, dry place, away from direct sunlight.

Formulations

• Liquid
• Capsules

Indications

• Constipation
• Dietary fiber supplementation
• Irritable bowel syndrome
• Diverticular disease
• Weight management

Dosage

Children: Refer to appropriate guidelines for specific dosage; generally taken with adequate fluid intake.

Adults: Refer to appropriate guidelines for specific dosage; generally taken with adequate fluid intake.

Mechanism of action

Cellulose acts primarily as a bulk-forming laxative. It absorbs water in the intestines, which increases stool bulk and stimulates peristalsis, thus facilitating bowel movements. Additionally, cellulose is not digestible by human enzymes, leading to fermentation by gut bacteria, which may enhance gut health and alter gut microbiota composition.

Pharmacodynamics

Cellulose increases stool weight and frequency of bowel movements. It works by retaining water in the intestines, leading to softer stools and improved passage through the gastrointestinal tract. The bulking effect of cellulose can help alleviate constipation and promote overall digestive health. It may also play a role in cholesterol reduction and glycemic control through its effects on digestion and absorption of nutrients.

Pharmacokinetics

Cellulose is not absorbed into the bloodstream due to its indigestible nature. Instead, it passes through the gastrointestinal tract, where it adds bulk to the stool. Its fermentation by colonic bacteria produces short-chain fatty acids, which may have beneficial effects on colon health. The onset of action for cellulose as a laxative can vary but is generally within 24 to 72 hours after ingestion.

Adverse effects

• Bloating
• Flatulence
• Diarrhea
• Abdominal discomfort

Precautions

• Use with caution in patients with a history of gastrointestinal disorders.
• Monitor for potential allergic reactions in sensitive individuals.

Pregnancy

Cellulose is generally considered safe during pregnancy as it is a non-toxic, indigestible fiber.

Breast-feeding

Cellulose is also considered safe during breastfeeding; it is excreted in breast milk in negligible amounts.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Powder
• Capsules
• Tablets
• Granules

Dosage

Children: Refer to the BNF for Children for appropriate dosing information in paediatric cases, especially in instances of overdose.

Adults: Refer to the BNF for specific dosing information based on clinical circumstances, particularly in cases of overdose.

Mechanism of action

Ethylene glycol is metabolized by alcohol dehydrogenase to glycoaldehyde, which is subsequently converted to glycolic, glyoxylic, and oxalic acids. These metabolites contribute to anion gap metabolic acidosis and are responsible for tissue injury through the formation of insoluble calcium oxalate crystals.

Pharmacodynamics

The toxicity of ethylene glycol arises from its metabolites, particularly glycolic and oxalic acids. These compounds induce metabolic acidosis, lead to renal failure through calcium oxalate crystal deposition in the kidneys, and can cause neurological impairment. The anion gap increases due to the accumulation of these acids, leading to complications such as cardiovascular instability and potential multi-organ failure.

Pharmacokinetics

Ethylene glycol is rapidly absorbed after oral ingestion. It undergoes first-pass metabolism primarily in the liver, where it is converted into its toxic metabolites. The elimination half-life of ethylene glycol varies but is generally prolonged in cases of renal impairment. Renal excretion of metabolites contributes to the duration of toxicity, necessitating prompt medical intervention in cases of overdose.

Adverse effects

• Metabolic acidosis
• Renal failure
• CNS depression
• Hypocalcemia
• Cardiovascular collapse
• Pulmonary edema

Precautions

• Use with caution in patients with renal impairment
• Monitor for signs of metabolic acidosis
• Evaluate electrolyte levels, particularly calcium

Pregnancy

There is limited data on the safety of ethylene glycol in pregnancy. It should only be used if clearly needed.

Breast-feeding

It is unknown if ethylene glycol is excreted in human milk. Caution is advised.

Storage

Store in a tightly closed container at room temperature, away from heat and moisture.

Formulations

• Liquid

Indications

• Food industry applications
• Culinary uses
• Food preservation

Dosage

Children: The dosage of hydrogenated fats in children should be approached with caution, and intake should be minimized due to the potential health risks associated with trans fats.

Adults: The dosage of hydrogenated fats varies widely based on dietary recommendations and individual health needs. It is important to limit the intake of trans fats due to their adverse health effects.

Mechanism of action

Hydrogenated fats primarily affect lipid metabolism and can alter the composition of cell membranes. The presence of trans fatty acids resulting from partial hydrogenation can raise low-density lipoprotein (LDL) cholesterol while lowering high-density lipoprotein (HDL) cholesterol, leading to an unfavorable lipid profile. This alteration in lipid levels contributes to the development of atherosclerosis and other cardiovascular diseases.

Pharmacodynamics

The pharmacodynamics of hydrogenated fats is largely associated with their impact on lipid metabolism and cardiovascular health. Trans fats can induce inflammatory responses and are thought to influence insulin resistance. The effects on cholesterol levels and inflammatory markers contribute to their association with increased risk of coronary heart disease.

Pharmacokinetics

The pharmacokinetics of hydrogenated fats involve absorption in the gastrointestinal tract, where they are emulsified and broken down by digestive enzymes. Once absorbed, they are transported via chylomicrons through the lymphatic system into the bloodstream. Hydrogenated fats are metabolized in the liver, where they can be re-esterified into triglycerides or incorporated into lipoproteins for distribution to tissues. The half-life and elimination of specific hydrogenated fats can vary based on their structure and the degree of hydrogenation.

Contra-indications

• Hypersensitivity to hydrogenated products
• Severe liver disease
• Active gastrointestinal bleeding

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Abdominal pain
• Headache
• Allergic reactions

Interactions

• May interact with anticoagulants leading to increased bleeding risk
• Potential interaction with other medications metabolized by the liver

Precautions

• Use with caution in patients with liver impairment
• Monitor for gastrointestinal side effects
• Assess for potential allergic reactions

Pregnancy

Use during pregnancy only if clearly needed and the benefits outweigh the risks.

Breast-feeding

Caution is advised; consult healthcare professionals for guidance.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Oral tablets
• Injectable forms
• Topical preparations

Mechanism of action

The hydroxyl group acts as a nucleophile, participating in various biochemical reactions, including the degradation of reactive oxygen species. It helps in the detoxification of oxidized guanosine triphosphate (GTP) and deoxyguanosine triphosphate (dGTP), which is critical for maintaining cellular integrity and function.

Pharmacodynamics

The presence of hydroxyl groups in compounds can significantly alter their pharmacological effects, enhancing solubility and reactivity. Hydroxyl groups can stabilize reactive intermediates, leading to increased efficacy in biochemical pathways, particularly in processes involving oxidative stress and cellular detoxification.

Pharmacokinetics

Hydroxyl-containing compounds typically exhibit variable absorption, distribution, metabolism, and excretion profiles depending on their specific structure. The pharmacokinetics of hydroxyl as a standalone entity is not well-defined, but its presence in larger molecules often influences their bioavailability and elimination.

Pregnancy

There is insufficient data to determine the safety of hydroxyl in pregnancy. Caution is advised.

Breast-feeding

There is no specific information available regarding the excretion of hydroxyl in human milk. Caution is advised.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Used as a filler in tablet formulations
• Serves as a binder in solid dosage forms
• Acts as a disintegrant to aid tablet dissolution
• Improves flow properties of powders in manufacturing

Dosage

Children: Refer to specific formulations and guidelines for dosing, as microcrystalline cellulose is used as an excipient and does not have a standard dosing regimen.

Adults: Refer to specific formulations and guidelines for dosing, as microcrystalline cellulose is used as an excipient and does not have a standard dosing regimen.

Mechanism of action

Microcrystalline cellulose functions primarily as a bulking agent and a stabilizer in pharmaceutical formulations. It does not exert pharmacological effects on its own but serves to provide structure and stability to the drug formulations, facilitating the release of the active pharmaceutical ingredient (API) during dissolution and absorption.

Pharmacodynamics

MCC does not have a pharmacodynamic profile as it is not an active drug. Its role is to enhance the physical properties of pharmaceutical products, ensuring uniformity, consistency, and stability of the drug formulation. Its ability to absorb water and swell aids in the disintegration of tablets in the gastrointestinal tract, promoting the release of the active ingredients.

Pharmacokinetics

As a non-digestible polysaccharide, microcrystalline cellulose is not absorbed in the gastrointestinal tract. It passes through the digestive system unchanged and is excreted in the feces. Its presence in the gastrointestinal tract can have a bulking effect, promoting bowel regularity without contributing calories.

Pregnancy

Microcrystalline cellulose is generally considered safe for use during pregnancy as it is not absorbed and is used as an excipient.

Breast-feeding

Microcrystalline cellulose is also considered safe during breastfeeding since it is not absorbed into the systemic circulation.

Storage

Store in a cool, dry place away from direct sunlight. Keep container tightly closed.

Formulations

• Tablets
• Capsules
• Powder

Indications

• Constipation
• Bowel preparation prior to surgical procedures or diagnostic tests

Dosage

Children: Refer to specific guidelines or BNF for Children for dosing information.

Adults: Refer to specific guidelines or BNF for detailed dosing information.

Mechanism of action

Polyethylene glycol works by osmotically retaining water in the intestinal lumen, which increases the water content of the stool. This enhances the passage of stool through the intestines and promotes bowel movements. The high molecular weight of polyethylene glycol prevents its absorption in the gastrointestinal tract, ensuring that it remains in the lumen to exert its effects.

Pharmacodynamics

The pharmacodynamic profile of polyethylene glycol involves its ability to increase stool water content, thereby reducing stool consistency and facilitating easier passage. It does not stimulate intestinal motility directly but rather relies on the osmotic effect to promote bowel evacuation. The onset of action typically occurs within 24 to 96 hours after ingestion.

Pharmacokinetics

Polyethylene glycol is not absorbed systemically, and its pharmacokinetics are characterized by its presence solely in the gastrointestinal tract. It is excreted unchanged in the stool. The volume of polyethylene glycol administered can influence the effectiveness and timing of its action, but its absorption is negligible, making systemic side effects rare.

Adverse effects

• Abdominal cramping
• Diarrhea
• Nausea
• Vomiting
• Bloating
• Flatulence

Precautions

• Use with caution in patients with gastrointestinal disorders or bowel obstruction.
• Ensure adequate hydration during use to prevent dehydration.

Pregnancy

Polyethylene glycol is generally considered safe during pregnancy, but should be used under medical supervision.

Breast-feeding

Polyethylene glycol is excreted in breast milk in very small amounts and is generally regarded as safe during breastfeeding.

Storage

Store at room temperature, away from moisture and heat.

Formulations

• Powder for oral solution
• Liquid formulation

Indications

• Hyperthyroidism
• Graves' disease
• Thyroid storm

Dosage

Children: Refer to the BNF

Adults: The usual initial dose of propylthiouracil in adults is 300 mg per day, divided into 3 doses. The maintenance dose is typically 100-150 mg per day, adjusted based on thyroid function tests.

Mechanism of action

Propylthiouracil acts by inhibiting the enzyme thyroid peroxidase, which is involved in the iodination of tyrosine residues in thyroglobulin, a precursor of thyroid hormones. By blocking this enzyme, PTU reduces the production of thyroxine (T4) and triiodothyronine (T3), leading to decreased thyroid hormone levels in circulation. Additionally, PTU inhibits the conversion of T4 to T3 in peripheral tissues, further contributing to its antithyroid effects.

Pharmacodynamics

The pharmacodynamic effects of propylthiouracil are primarily centered around its ability to lower thyroid hormone levels, which helps alleviate symptoms of hyperthyroidism such as increased heart rate, weight loss, and anxiety. The onset of action can vary, but therapeutic effects may be observed within several weeks of initiation. Monitoring thyroid function tests is essential to assess the efficacy and adjust dosing as needed.

Pharmacokinetics

Propylthiouracil is well absorbed from the gastrointestinal tract, though its bioavailability can be affected by factors such as food intake. The drug is extensively metabolized in the liver, and its elimination half-life averages around 1-2 hours. Most of the drug is excreted in urine as metabolites. It is important to note that due to its rapid metabolism, multiple daily doses may be required to maintain therapeutic levels.

Interactions

• propylthiouracil+metyrapone: Severe (decreases effects)

Dosage

Children: Refer to specific drug formulations and product labels as purified substances can vary widely in their use and dosing.

Adults: Refer to specific drug formulations and product labels as purified substances can vary widely in their use and dosing.

Mechanism of action

The mechanism of action for purified compounds varies widely depending on the specific substance. Generally, purified drugs exert their effects by interacting with specific biological targets, such as receptors, enzymes, or ion channels, leading to a desired therapeutic effect. This interaction can involve binding to receptors to activate or inhibit signaling pathways, modulating enzymatic activity, or altering physiological processes.

Pharmacodynamics

Pharmacodynamics describes the effects of a drug on the body and the relationship between drug concentration and effect. For purified drugs, this can involve dose-response relationships and the time course of their action. The purified form often enhances potency and reduces variability in response among patients, which can lead to more predictable therapeutic outcomes. The overall effect is determined by the drug's affinity for its target, the efficacy of the drug-receptor interaction, and the downstream signaling pathways activated as a result of this interaction.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion (ADME) of a drug. For purified substances, absorption can be more efficient due to the absence of impurities that may affect solubility or stability. Distribution may also be enhanced, leading to higher bioavailability. Metabolism can be influenced by the structure of the purified compound, as it may be metabolized more readily by liver enzymes. Excretion typically occurs through the kidneys or liver, depending on the molecular characteristics of the purified drug.

Pregnancy

Consult with a healthcare professional, as the safety of purified forms of medications during pregnancy may vary depending on the specific substance.

Breast-feeding

Consult with a healthcare professional, as the safety of purified forms of medications during breastfeeding may vary depending on the specific substance.

Storage

Store in a cool, dry place, away from light and moisture, and keep out of reach of children.

Dosage

Children: Refer to BNF for Children for appropriate dosing guidelines for paediatric patients.

Adults: Refer to specific guidelines or BNF for the appropriate dosing of substituted drugs as they vary widely based on the specific compound and its clinical use.

Mechanism of action

The mechanism of action for substituted drugs typically involves interaction with specific biological targets such as receptors, enzymes, or ion channels. By binding to these targets, substituted drugs can modulate various physiological processes, leading to desired therapeutic effects, such as analgesia, anti-inflammatory action, or modulation of neurotransmitter activity.

Pharmacodynamics

Pharmacodynamics of substituted drugs depends on their specific structure and target interactions. Generally, they exert effects through receptor activation or inhibition, leading to alterations in signaling pathways. This can result in enhanced or diminished cellular responses, contributing to the overall therapeutic outcome. The potency and efficacy of these drugs can vary widely based on their chemical modifications.

Pharmacokinetics

The pharmacokinetics of substituted drugs involves absorption, distribution, metabolism, and excretion (ADME). Factors such as the lipophilicity, molecular weight, and chemical stability of the substituents can affect how the drug is absorbed in the gastrointestinal tract, distributed throughout the body, metabolized by the liver, and ultimately excreted through the kidneys. Variations in these parameters will influence the drug's bioavailability, half-life, and duration of action.

Pregnancy

Consult healthcare provider before use. Safety during pregnancy has not been established.

Breast-feeding

Consult healthcare provider before use. Limited data available on safety during breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Allergic reactions
• Asthma
• Rheumatoid arthritis
• Systemic lupus erythematosus
• Multiple sclerosis exacerbations
• Certain cancers
• Inflammatory bowel disease
• Skin disorders

Dosage

Children: Refer to the BNF for Children for appropriate pediatric dosing, as it is condition-specific and varies with age and weight.

Adults: Refer to the specific clinical guidelines or BNF for details on dosing, as it varies based on the condition being treated.

Mechanism of action

Dexamethasone, the active component of Wincoat, binds to the glucocorticoid receptor, leading to alterations in gene expression. This results in decreased production of pro-inflammatory cytokines and an increase in anti-inflammatory proteins. The overall effect is the suppression of immune response and inflammation.

Pharmacodynamics

Dexamethasone exhibits potent anti-inflammatory effects by inhibiting the migration of leukocytes and suppressing the expression of inflammatory mediators. It also affects carbohydrate metabolism, protein metabolism, and electrolyte balance, leading to various physiological effects. The drug's immunosuppressive properties are crucial in managing conditions where the immune system is overactive.

Pharmacokinetics

Dexamethasone is well absorbed when administered orally and reaches peak plasma concentrations within 1-2 hours. It is extensively metabolized in the liver, primarily by the cytochrome P450 system. The elimination half-life ranges from 3 to 5 hours, with metabolites excreted mainly in urine. Dexamethasone's protein binding is approximately 77%, and it has a large volume of distribution, indicating extensive tissue distribution.

Pregnancy

There is limited data on the use of Wincoat during pregnancy. It is advised to weigh the potential benefits against risks before prescribing.

Breast-feeding

It is unknown whether Wincoat is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Mechanism of action

Clopidogrel is activated via a 2 steps reaction to an active thiol-containing metabolite. This active form is a platelet inhibitor that irreversibly binds to P2Y₁₂ ADP receptors on platelets. This binding prevents ADP binding to P2Y₁₂ receptors, activation of the glycoprotein GPIIb/IIIa complex, and platelet aggregation. Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. This action is irreversible. Consequently, platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days). Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP. The P2Y12 receptor plays a crucial role in the regulation of platelet activation by several agonists, which is irreversibly antagonized by the active metabolite of clopidogrel, a widely used anti-thrombotic drug. In this study, we investigated whether reduction of platelet reactivity leads to reduced inflammatory responses using a rat model of erosive arthritis. We evaluated the effect of clopidogrel on inflammation in Lewis rats in a peptidoglycan polysaccharide (PG-PS)-induced arthritis model with four groups of rats: 1) untreated, 2) clopidogrel-treated, 3) PG-PS-induced, and 4) PG-PS-induced and clopidogrel-treated. There were significant differences between the PG-PS+clopidogrel group when compared to the PG-PS group including: increased joint diameter and clinical manifestations of inflammation, elevated plasma levels of pro-inflammatory cytokines (IL-1 beta, interferon (IFN) gamma, and IL-6), an elevated neutrophil blood count and an increased circulating platelet count. Plasma levels of IL-10 were significantly lower in the PG-PS+clopidogrel group compared to the PG-PS group. Plasma levels of platelet factor 4 (PF4) were elevated in both the PG-PS and the PG-PS+clopidogrel groups, however PF4 levels showed no difference upon clopidogrel treatment, suggesting that the pro- inflammatory effect of clopidogrel may be due to its action on cells other than platelets. Histology indicated an increase in leukocyte infiltration at the inflammatory area of the joint, increased pannus formation, blood vessel proliferation, subsynovial fibrosis and cartilage erosion upon treatment with clopidogrel in PG-PS-induced arthritis animals. In summary, animals treated with clopidogrel showed a pro-inflammatory effect in the PG-PS-induced arthritis animal model, which might not be mediated by platelets.

Pharmacodynamics

Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. It has a long duration of action as it is taken once daily and a large therapeutic window as it is given in doses of 75-300mg daily.

Mechanism of action

Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. As a diurectic mannitol induces diuresis because it is not reabsorbed in the renal tubule, thereby increasing the osmolality of the glomerular filtrate, facilitating excretion of water, and inhibiting the renal tubular reabsorption of sodium, chloride, and other solutes. Mannitol promotes the urinary excretion of toxic materials and protects against nephrotoxicity by preventing the concentration of toxic substances in the tubular fluid. As an Antiglaucoma agent mannitol levates blood plasma osmolarity, resulting in enhanced flow of water from the eye into plasma and a consequent reduction in intraocular pressure. As a renal function diagnostic aid mannitol is freely filtered by the glomeruli with less than 10% tubular reabsorption. Therefore, its urinary excretion rate may serve as a measurement of glomerular filtration rate (GFR). The exact mechanism of action of inhaled mannitol in the symptomatic maintenance treatment of cystic fibrosis remains unclear. It is hypothesized that mannitol produces an osmotic gradient across the airway epithelium that draws fluid into the extracellular space and alters the properties of the airway surface mucus layer, allowing easier mucociliary clearance. MANNITOL IS.../USED/ IN PROPHYLAXIS OF ACUTE RENAL FAILURE. IT IS USED FOR THIS PURPOSE IN CONDITIONS AS DIVERSE AS CARDIOVASCULAR OPERATIONS, SEVERE TRAUMATIC INJURY, OPERATIONS IN THE PRESENCE OF SEVERE JAUNDICE, AND MGMNT OF HEMOLYTIC TRANSFUSION REACTIONS. IN EACH OF THESE CONDITIONS, A PRECIPITOUS FALL IN THE FLOW OF URINE MAY BE ANTICIPATED EITHER AS THE RESULT OF AN ACUTELY REDUCED FILTRATION RATE OR FROM ACUTE CHANGES IN TUBULAR PERMEABILITY. THE LATTER MAY BE CONSEQUENCE OF THE PRESENCE OF NOXIOUS AGENT WITHIN THE TUBULAR FLUID IN EXCESSIVELY HIGH CONCN, IN SOME INSTANCES SUFFICIENT TO RESULT IN ACTUAL PRECIPITATION. IN THESE SITUATIONS, MANNITOL EXERTS OSMOTIC EFFECT WITHIN THE TUBULAR FLUID, INHIBITS WATER REABSORPTION, & MAINTAINS THE RATE OF URINE FLOW. ...CONCN OF TOXIC AGENT WITHIN TUBULAR FLUID DOES NOT REACH EXCESSIVELY HIGH LEVELS THAT OTHERWISE WOULD HAVE BEEN ACHIEVED BY MORE COMPLETE REABSORPTION OF WATER. ...EVEN THOUGH /GLOMERULAR/ FILTRATION RATE IS REDUCED, MANNITOL IS STILL FILTERED @ GLOMERULUS. THE TUBULAR IMPERMEABILITY TO MANNITOL IS NOT ALTERED BY ACUTE RENAL ISCHEMIA OF SHORT DURATION. HENCE, THE MANNITOL THAT IS FILTERED IS ALSO EXCRETED IN THE VOIDED URINE. UNREABSORBED SOLUTE LIMITS BACK DIFFUSION OF WATER. ...URINE VOL CAN BE MAINTAINED EVEN IN PRESENCE OF DECR GLOMERULAR FILTRATION.

Pharmacodynamics

Chemically, mannitol is an alcohol and a sugar, or a polyol; it is similar to xylitol or sorbitol. However, mannitol has a tendency to lose a hydrogen ion in aqueous solutions, which causes the solution to become acidic. For this reason, it is not uncommon to add a substance to adjust its pH, such as sodium bicarbonate. Mannitol is commonly used to increase urine production (diuretic). It is also used to treat or prevent medical conditions that are caused by an increase in body fluids/water (e.g., cerebral edema, glaucoma, kidney failure). Mannitol is frequently given along with other diuretics (e.g., furosemide, chlorothiazide) and/or IV fluid replacement. Inhaled mannitol has the possibility to cause bronchospasm and hemoptysis; the occurrence of either should lead to discontinuation of inhaled mannitol.

Mechanism of action

Ethylene glycol is metabolized by alcohol dehydrogenase to glycoaldehyde, which is then metabolized to glycolic, glyoxylic, and oxalic acids. These acids, along with excess lactic acid are responsible for the anion gap metabolic acidosis. Oxalic acid readily precipitates with calcium to form insoluble calcium oxalate crystals. Tissue injury is caused by widespread deposition of oxalate crystals and the toxic effects of glycolic and glyoxylic acids.